RxDoctor Payments Data

Alice Powell

Physician Assistant · Baker, LANPI 1386694560

Payments from drug & device makers

$3,609in general payments, 2019–2025

Across 206 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$532
  • Bayer$421
  • Novo Nordisk$356
  • Takeda Pharmaceuticals U.S.A., Inc.$313
  • Abbott$296
  • Acadia Pharmaceuticals Inc$190
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$3,56799%
  • Education$421%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,609 in reported general payments places this provider in the 85th percentile of 1,246 physician assistant providers in Louisiana.

See all physician assistant providers in Louisiana

Medicare billing

Part B allowed, 2024
$19,696
Medicare patients
71
Services billed
330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide50$73,207
JardianceEmpagliflozin42$36,139
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,503
SynthroidLevothyroxine Sodium28$1,865
Albuterol Sulfate HfaAlbuterol Sulfate49$1,330
Quetiapine Fumarate27$973
Rosuvastatin Calcium69$885
Diclofenac Sodium18$803
Pantoprazole Sodium76$655
Omeprazole30$610
Amlodipine Besylate76$559
Atorvastatin Calcium67$533
Gabapentin48$514
Levocetirizine Dihydrochloride33$491
Potassium Chloride14$490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$532$73,20750 claims
Boehringer IngelheimJardiance$127$36,13942 claims
GSKTrelegy Ellipta$150$7,50311 claims
AbbVieSynthroid$148$1,86528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,246 physician assistant providers in Louisiana.

Other physician assistant in Baker

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →